AstraZeneca agrees to buy MedImmune

AstraZeneca agreed Monday to pruchase U.S. biotechnology company MedImmune for $15.2 billion in cash to gain flu vaccines and an
antiviral treatment for babies.

AstraZeneca has recently dropped an important experimental heart medicine, the fourth setback for its laboratories since February
2006.

AstraZeneca is reliant on its top three drugs, Nexium, Seroquel for schizophrenia and the Crestor cholesterol medicine, for profit growth.